Obesity Drugs Could Get Lift From Part D Legislation, AMA Policy
This article was originally published in The Pink Sheet Daily
Two events lead the way to greater coverage and reimbursement for obesity drugs: a bipartisan, bicameral bill that would remove Medicare Part D’s ban on covering obesity drugs and AMA’s recognition of obesity as a disease.
You may also be interested in...
Takeda preps for cost-cutting program; Astellas clears path for Xtandi; and Eisai leans on Belviq in the U.S. with aggressive coverage program.
The summary report of an interim analysis of the ongoing LIGHT clinical trial evaluating the cardiovascular safety of the obesity medicine can form the basis of a resubmission of the Contrave NDA, the company announced, shaving some time off the PDUFA clock.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.